Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMET12 plus toripalimab in EGFR-positive advanced solid tumors
ChiCTR2300069123Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SMET12 and toripalimab in melanoma, head and neck squamous cell carcinoma (HNSCC), transitional cell carcinoma (TCC) and 4 more (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Efficacy, Objective response rate (ORR) and 3 more. Started Mar 2023; status: recruiting.
02
Drugs
SMET12toripalimab
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)transitional cell carcinoma (TCC)gastric cancer (GC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300069123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069123.